UNIVERSI
TÄ
TS-
BIBLIOTHEK
P
ADERBORN
Anmelden
Menü
Menü
Start
Hilfe
Blog
Weitere Dienste
Neuerwerbungslisten
Fachsystematik Bücher
Erwerbungsvorschlag
Bestellung aus dem Magazin
Fernleihe
Einstellungen
Sprache
Deutsch
Deutsch
Englisch
Farbschema
Hell
Dunkel
Automatisch
Sie befinden Sich nicht im Netzwerk der Universität Paderborn. Der Zugriff auf elektronische Ressourcen ist
gegebenenfalls
nur via VPN oder Shibboleth (DFN-AAI) möglich.
mehr Informationen...
Universitätsbibliothek
Katalog
Suche
Details
Zur Ergebnisliste
Ergebnis 5 von 12
Datensatz exportieren als...
BibTeX
Vitamin D Control of Hematopoietic Cell Differentiation and Leukemia
Journal of cellular biochemistry, 2015-08, Vol.116 (8), p.1500-1512
Studzinski, George P.
Harrison, Jonathan S.
Wang, Xuening
Sarkar, Surojit
Kalia, Vandana
Danilenko, Michael
2015
Details
Autor(en) / Beteiligte
Studzinski, George P.
Harrison, Jonathan S.
Wang, Xuening
Sarkar, Surojit
Kalia, Vandana
Danilenko, Michael
Titel
Vitamin D Control of Hematopoietic Cell Differentiation and Leukemia
Ist Teil von
Journal of cellular biochemistry, 2015-08, Vol.116 (8), p.1500-1512
Ort / Verlag
United States: Blackwell Publishing Ltd
Erscheinungsjahr
2015
Link zum Volltext
Quelle
Wiley Online Library - AutoHoldings Journals
Beschreibungen/Notizen
It is now well known that in the mammalian body vitamin D is converted by successive hydroxylations to 1,25‐dihydroxyvitamin D (1,25D), a steroid‐like hormone with pleiotropic properties. These include important contributions to the control of cell proliferation, survival and differentiation, as well as the regulation of immune responses in disease. Here, we present recent advances in current understanding of the role of 1,25D in myelopoiesis and lymphopoiesis, and the potential of 1,25D and analogs (vitamin D derivatives; VDDs) for the control of hematopoietic malignancies. The reasons for the unimpressive results of most clinical studies of the therapeutic effects of VDDs in leukemia and related diseases may include the lack of a precise rationale for the conduct of these studies. Further, clinical trials to date have generally used extremely heterogeneous patient populations and, in many cases, small numbers of patients, generally without controls. Although low calcemic VDDs have been used and combined with agents that can increase the leukemia cell killing or differentiation effects in acute leukemias, the sequencing of agents used for combination therapy should to be more clearly delineated. Most importantly, it is recommended that in future clinical trials the rationale for the basis of the enhancing action of drug combinations should be clearly articulated and the effects on anticancer immunity should also be evaluated. J. Cell. Biochem. 116: 1500–1512, 2015. © 2015 Wiley Periodicals, Inc.
Sprache
Englisch
Identifikatoren
ISSN: 0730-2312
eISSN: 1097-4644
DOI: 10.1002/jcb.25104
Titel-ID: cdi_proquest_miscellaneous_1690651319
Format
–
Schlagworte
Animals
,
Antineoplastic Combined Chemotherapy Protocols - administration & dosage
,
Antineoplastic Combined Chemotherapy Protocols - pharmacology
,
CALCITRIOL
,
Cell Differentiation - drug effects
,
Clinical Trials as Topic
,
HEMATOPOIESIS
,
Hematopoiesis - drug effects
,
Humans
,
LEUKEMIA
,
Leukemia - drug therapy
,
Leukemia - pathology
,
VITAMIN D
,
Vitamin D - administration & dosage
,
Vitamin D - analogs & derivatives
,
Vitamin D - pharmacology
,
Vitamins - administration & dosage
,
Vitamins - pharmacology
Weiterführende Literatur
Empfehlungen zum selben Thema automatisch vorgeschlagen von
bX